Dear Subscriber, |
Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories. To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y . |
Alcohol / Addiction / Illegal Drugs News | |
Study Finds Kaiser Permanente Early Start Program Could Save US Billions In Health Costs A program for women at risk of substance abuse during pregnancy could save nearly $2 billion annually in health care costs if implemented nationwide, according to a Kaiser Permanente study published online in the American College of Obstetricians and Gynecologists' journal, Obstetrics & Gynecology. | 31 Dec 2011 |
Allergy News | |
Get Ready For Spring - Hay Fever Worse In Spring Than Summer Hay fever (runny nose, sneezing, itchy eyes) is caused by an allergy to pollen, and most commonly to grass pollen. These tiny grains bring misery to sufferers through spring and summer and pollen levels are often included as part of weather reports to help sufferers prepare. | 31 Dec 2011 |
Alzheimer's / Dementia News | |
Why Older People Lose Their Memory The stereotype of the old forgetful person whose memory often fails him is widely held, but the reason for its appearance was never really pinpointed. Much like gray hair and wrinkles, it was just thought to be part of growing old. | 31 Dec 2011 |
Biology / Biochemistry News | |
NPL Models The Extracellular Matrix Scientists at the National Physical Laboratory (NPL) have created a functional model of the native extracellular matrix that provides structural support to cells to aid growth and proliferation. | 31 Dec 2011 |
Human Skull Study Causes Evolutionary Headache Scientists studying a unique collection of human skulls have shown that changes to the skull shape thought to have occurred independently through separate evolutionary events may have actually precipitated each other. | 31 Dec 2011 |
Cancer / Oncology News | |
FDA To Review Potential New Use Of XGEVA® (Denosumab) At Oncologic Drugs Advisory Committee Meeting Amgen (NASDAQ: AMGN) announced the U.S. Food and Drug Administration (FDA) has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases. | 31 Dec 2011 |
Cardiovascular / Cardiology News | |
Abbott Initiates Clinical Trial To Study Drug Eluting Bioresorbable Therapy For Treatment Of Peripheral Artery Disease Abbott (NYSE: ABT) announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit™ drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries that have resulted in claudication (leg pain upon walking). | 31 Dec 2011 |
Clinical Trials / Drug Trials News | |
Denali Concrete Management Inc. Announces The Commencement Of Patient Enrollment For The Phase 3 Dry Eye Syndrome Study Denali Concrete Management Inc. (OTCBB: DCMG) announced that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome. | 31 Dec 2011 |
Abbott Initiates Clinical Trial To Study Drug Eluting Bioresorbable Therapy For Treatment Of Peripheral Artery Disease Abbott (NYSE: ABT) announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit™ drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries that have resulted in claudication (leg pain upon walking). | 31 Dec 2011 |
"Science" Names HIV Prevention Trial As Breakthrough Of The Year Science named the HIV Prevention Trials Network (HPTN) 052 study "Breakthrough of the Year." FHI 360 congratulates our HPTN 052 collaborating partners on this important achievement. This is the second year in a row that Science selected a trial for which FHI 360 provided scientific leadership and operational support. | 31 Dec 2011 |
Endocrinology News | |
Obesity-Induced Brain Changes May Be Reason Weight Control Is So Hard The biggest obstacle to the successful treatment of obesity is the tendency to regain weight lost through diet and exercise, and evidence is increasing that this could be due to physiological causes. | 31 Dec 2011 |
Eye Health / Blindness News | |
Denali Concrete Management Inc. Announces The Commencement Of Patient Enrollment For The Phase 3 Dry Eye Syndrome Study Denali Concrete Management Inc. (OTCBB: DCMG) announced that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome. | 31 Dec 2011 |
Hearing / Deafness News | |
Do You Hear What I Hear? Noise Exposure Surrounds Us Nine out of 10 city dwellers may have enough harmful noise exposure to risk hearing loss, and most of that exposure comes from leisure activities.Historically, loud workplaces were blamed for harmful noise levels. | 31 Dec 2011 |
Heart Disease News | |
Abbott Initiates Clinical Trial To Study Drug Eluting Bioresorbable Therapy For Treatment Of Peripheral Artery Disease Abbott (NYSE: ABT) announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit™ drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries that have resulted in claudication (leg pain upon walking). | 31 Dec 2011 |
HIV / AIDS News | |
"Science" Names HIV Prevention Trial As Breakthrough Of The Year Science named the HIV Prevention Trials Network (HPTN) 052 study "Breakthrough of the Year." FHI 360 congratulates our HPTN 052 collaborating partners on this important achievement. This is the second year in a row that Science selected a trial for which FHI 360 provided scientific leadership and operational support. | 31 Dec 2011 |
Infectious Diseases / Bacteria / Viruses News | |
Disease-Causing Strains Of Fusarium Prevalent In Plumbing Drains A study examining the prevalence of the fungus Fusarium in bathroom sink drains suggests that plumbing systems may be a common source of human infections.In the first extensive survey of its kind, researchers in Penn State's College of Agricultural Sciences sampled nearly 500 sink drains from 131 buildings -- businesses, homes, university dormitories and public facilities -- in Pennsylvania, Maryland, Virginia, North Carolina, South Carolina, Georgia, Florida and California. | 31 Dec 2011 |
Neurology / Neuroscience News | |
Why Older People Lose Their Memory The stereotype of the old forgetful person whose memory often fails him is widely held, but the reason for its appearance was never really pinpointed. Much like gray hair and wrinkles, it was just thought to be part of growing old. | 31 Dec 2011 |
Obesity-Induced Brain Changes May Be Reason Weight Control Is So Hard The biggest obstacle to the successful treatment of obesity is the tendency to regain weight lost through diet and exercise, and evidence is increasing that this could be due to physiological causes. | 31 Dec 2011 |
UCLA Neuroscientists Demonstrate Crucial Advances In 'Brain Reading' At UCLA's Laboratory of Integrative Neuroimaging Technology, researchers use functional MRI brain scans to observe brain signal changes that take place during mental activity. They then employ computerized machine learning (ML) methods to study these patterns and identify the cognitive state - or sometimes the thought process - of human subjects. | 31 Dec 2011 |
Obesity / Weight Loss / Fitness News | |
Obesity-Induced Brain Changes May Be Reason Weight Control Is So Hard The biggest obstacle to the successful treatment of obesity is the tendency to regain weight lost through diet and exercise, and evidence is increasing that this could be due to physiological causes. | 31 Dec 2011 |
More Reasons To Keep This New Year's Weight Loss Resolution Uncovered By Ben-Gurion U Researchers Long-term healthy dietary interventions frequently induce a rapid weight decline, mainly in the first four to six months, followed by weight stabilization or regain, despite continued dieting. | 31 Dec 2011 |
Pain / Anesthetics News | |
Double Check Dose Before Giving Acetaminophen To Infants, FDA The US Food and Drug Administration (FDA) is urging consumers to double check the label on liquid acetaminophen products marketed to infants and children before giving it to them. The popular pain reliever is marketed under various brands, including Tylenol, PediaCare, Triaminic and Little Fevers. | 31 Dec 2011 |
Pediatrics / Children's Health News | |
Double Check Dose Before Giving Acetaminophen To Infants, FDA The US Food and Drug Administration (FDA) is urging consumers to double check the label on liquid acetaminophen products marketed to infants and children before giving it to them. The popular pain reliever is marketed under various brands, including Tylenol, PediaCare, Triaminic and Little Fevers. | 31 Dec 2011 |
Pharma Industry / Biotech Industry News | |
Denali Concrete Management Inc. Announces The Commencement Of Patient Enrollment For The Phase 3 Dry Eye Syndrome Study Denali Concrete Management Inc. (OTCBB: DCMG) announced that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome. | 31 Dec 2011 |
FDA To Review Potential New Use Of XGEVA® (Denosumab) At Oncologic Drugs Advisory Committee Meeting Amgen (NASDAQ: AMGN) announced the U.S. Food and Drug Administration (FDA) has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases. | 31 Dec 2011 |
Pregnancy / Obstetrics News | |
Study Finds Kaiser Permanente Early Start Program Could Save US Billions In Health Costs A program for women at risk of substance abuse during pregnancy could save nearly $2 billion annually in health care costs if implemented nationwide, according to a Kaiser Permanente study published online in the American College of Obstetricians and Gynecologists' journal, Obstetrics & Gynecology. | 31 Dec 2011 |
Preventive Medicine News | |
"Science" Names HIV Prevention Trial As Breakthrough Of The Year Science named the HIV Prevention Trials Network (HPTN) 052 study "Breakthrough of the Year." FHI 360 congratulates our HPTN 052 collaborating partners on this important achievement. This is the second year in a row that Science selected a trial for which FHI 360 provided scientific leadership and operational support. | 31 Dec 2011 |
Public Health News | |
Disease-Causing Strains Of Fusarium Prevalent In Plumbing Drains A study examining the prevalence of the fungus Fusarium in bathroom sink drains suggests that plumbing systems may be a common source of human infections.In the first extensive survey of its kind, researchers in Penn State's College of Agricultural Sciences sampled nearly 500 sink drains from 131 buildings -- businesses, homes, university dormitories and public facilities -- in Pennsylvania, Maryland, Virginia, North Carolina, South Carolina, Georgia, Florida and California. | 31 Dec 2011 |
Regulatory Affairs / Drug Approvals News | |
FDA To Review Potential New Use Of XGEVA® (Denosumab) At Oncologic Drugs Advisory Committee Meeting Amgen (NASDAQ: AMGN) announced the U.S. Food and Drug Administration (FDA) has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases. | 31 Dec 2011 |
Double Check Dose Before Giving Acetaminophen To Infants, FDA The US Food and Drug Administration (FDA) is urging consumers to double check the label on liquid acetaminophen products marketed to infants and children before giving it to them. The popular pain reliever is marketed under various brands, including Tylenol, PediaCare, Triaminic and Little Fevers. | 31 Dec 2011 |
Stroke News | |
Why Older People Lose Their Memory The stereotype of the old forgetful person whose memory often fails him is widely held, but the reason for its appearance was never really pinpointed. Much like gray hair and wrinkles, it was just thought to be part of growing old. | 31 Dec 2011 |
Water - Air Quality / Agriculture News | |
Climate Sensitivity Greater Than Previously Believed Many of the particles in the atmosphere are produced by the natural world, and it is possible that plants have in recent decades reduced the effects of the greenhouse gases to which human activity has given rise. | 31 Dec 2011 |
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y . |
Tidak ada komentar:
Posting Komentar